Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 1/20 | 0.45 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.35 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23795922 | 0.81 | PSMD14 (0.50) | PSMD14POLBCA12CA1CA2 | |
| SCHEMBL23796376 | 0.80 | KDM4E (0.49) | PSMD14MGAMHCAR2POLBCA1 | |
| SCHEMBL15861797 | 0.78 | PSMD14 (0.67) | PSMD14MGAMHCAR2POLBCA12 | |
| SCHEMBL533275 | 0.77 | PRNP (0.42) | MEN1ALDH1A1LMNAKMT2ATSHR | |
| SCHEMBL31654043 | 0.77 | PSMD14 (0.45) | PSMD14MGAMHCAR2POLBTTR | |
| SCHEMBL23796197 | 0.76 | MAPT (0.43) | PSMD14MGAMHCAR2POLBP4HTM | |
| SCHEMBL23796031 | 0.75 | EGLN1 (0.52) | PSMD14MGAMHCAR2POLBKDM4E | |
| SCHEMBL23796443 | 0.74 | KMT2A (0.40) | PSMD14MGAMHCAR2POLBKDM4E | |
| SCHEMBL2319227 | 0.74 | LMNA (0.33) | LMNA | |
| SCHEMBL31328548 | 0.74 | CA12 (0.38) | CA12CA1CA9LMNAEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4358948-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230053649-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2022272036-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-3877356-A1 | BICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| CN-113302175-A | Bicyclic compounds | 维瓦斯治疗公司 | 2021-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053649-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | PSMD14 1048/4885MGAM 3167/4885HCAR2 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.